The study aims to test non-inferiority of bisoprolol-first vs. enalapril-first regarding death and hospitalization, and if bisoprolol-first shows superiority, it could change the paradigm of initiating CHF therapy with β-blockers instead of ACE inhibitors. Here, ACE is linked to congestive heart failure.